Who is sponsoring NCT00052130?

NCT00052130 is sponsored by CancerVax Corporation.

What condition does NCT00052130 study?

NCT00052130 studies Malignant Melanoma.

What drugs are being tested in NCT00052130?

Interventions: CancerVax vaccine (CANVAXIN).

What is the status of NCT00052130?

NCT00052130 is currently UNKNOWN.

Last reviewed 2005-06-23 · How we verify

Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma

NCT00052130 Phase 3 UNKNOWN

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Details

Lead sponsor	CancerVax Corporation
Phase	Phase 3
Status	UNKNOWN
Enrolment	1118

Conditions

Malignant Melanoma

Interventions

CancerVax vaccine (CANVAXIN)

Countries

United States, Australia, Brazil, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Switzerland, United Kingdom